Systemic Sclerosis May Be Caused by Common Pathologic Clusters in Different Tissues
Researchers investigated the common and tissue-specific pathways involved in the different tissues of patients with systemic sclerosis.
Scleroderma
Factors Influencing Improved Survival in Systemic Sclerosis-Associated PAH
Pulmonary arterial hypertension with systemic sclerosis associated-survival improved over time among patients aged 70 years or younger, but not among the elderly.
Ambrisentan May Improve Certain Parameters of Elevated Pulmonary Arterial Pressure in SSc
This study evaluated the effect of ambrisentan on mean pulmonary arterial pressure in patients with systemic sclerosis and mildly elevated pulmonary hypertension.
Cardiopulmonary Exercise Testing Plus Screening Algorithm Useful in SSc-Related Pulmonary Hypertension
Researchers evaluated whether cardiopulmonary exercise testing could improve the performance of the DETECT screening approach in systemic sclerosis-related pulmonary arterial hypertension.
Specific Factors Identify Patients at Risk for Disease Progression in SSc Clinical Trials
Researchers identified predictive factors associated with mortality and worsening of organ function in diffuse systemic sclerosis.
Skin Improvement Parallels Early Diffuse Cutaneous SSc Improvement
Disease improvement parallels skin improvement in early dcSSc — this is important for prognosis, and reflects the value of mRSS as an outcome measure in trials.
Abatacept Well-Tolerated But Has Minimal Benefit in Diffuse Cutaneous Systemic Sclerosis
Researchers assessed the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).
Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?
Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.
Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?
Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.
SSc-PAH Risk Category Improves With Ambrisentan and Tadalafil Combination Therapy
Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.
Next post in Scleroderma
